Intuitive Surgical is expensive for a reason, and the reason is that the growth engine still looks intact. At 50.9 times trailing earnings, ISRG is not a stock for bargain hunters, but that multiple keeps getting defended by a business growing revenue 20.5% and EPS 22.3% while maintaining a 28.2% net margin. The real story is not a peak-cycle medtech name running on hype; it is a category leader still compounding through procedure growth, installed-base expansion, and da Vinci 5 adoption ahead of the July 16 earnings catalyst.
The cleanest number in the bull case is procedure growth. In Q1 2026, worldwide procedures across da Vinci and Ion grew about 17% year over year, and management still guided full-year 2026 da Vinci procedure growth of roughly 13.5% to 15.5%. That matters more than the headline P/E because procedures are the demand signal that feeds the recurring revenue model, and ISRG is still posting the kind of utilization-driven growth most large-cap device names simply do not have.
The second pillar is installed-base expansion, which keeps widening the moat. As of March 31, 2026, Intuitive had 11,395 da Vinci systems installed, up 12% from 10,189 a year earlier. That is why the premium multiple has held up through repeated valuation scares: every new system expands the future stream of instruments, accessories, service, and procedure revenue, and the company is converting that scale into elite profitability, with a 66.3% gross margin and 30.5% operating margin. The TickerSpark Score captures that profile well, with a 95 Profitability score and 90 Growth score even though the Valuation score sits at just 43.
The third piece is that da Vinci 5 is already behaving like a real upgrade cycle, not a slide-deck promise. Intuitive placed 232 da Vinci 5 systems in Q1 out of 431 total da Vinci placements, and management followed that with a May product update highlighting additional ecosystem enhancements. That helps explain why ISRG has beaten earnings estimates in seven straight quarters, including an 18.5% beat in April. Premium stocks stay premium when execution keeps outrunning expectations, and that has been the pattern here.
The pushback is obvious enough: 50.9 times earnings and 14.26 times sales leave very little room for a stumble. ISRG has also badly lagged healthcare this year, down 24.2% versus a 5.3% gain for XLV, which tells you the market has already punished the stock when valuation anxiety takes over. Add in the fact that shares still sit below the 50-day and 200-day moving averages, and the technical picture is not exactly screaming "all clear."
That critique is real, but it still misses the bigger point. A rich multiple is a problem when growth is fading toward ordinary levels; ISRG is still putting up 20.5% revenue growth, 23.0% net income growth, and double-digit installed-base expansion with a 28.2% net margin. Even compared with peers, the premium is tied to quality: ResMed carries a much lower 19.46 P/E, but it is also growing revenue just 9.8%, while Repligen trades at 79.11 times earnings despite a far thinner 6.7% net margin. ISRG is not cheap, but the valuation argument falls apart when the underlying business keeps producing elite growth and elite margins at the same time.
That leaves ISRG looking like a stock we would still lean into on the thesis, not fade on the sticker price alone. The setup into July 16 is straightforward: if procedure growth, da Vinci 5 placements, and utilization trends hold anywhere near recent levels, the premium multiple remains earned. Strongly positive recent sentiment and above-average buying interest on the latest 5.9% move suggest investors are already positioning for that possibility.
The line that would change our mind is not the P/E ratio by itself. It would be evidence that procedure growth is slipping materially below the company’s own mid-teens framework or that da Vinci 5 adoption was front-loaded rather than durable. Until that shows up, ISRG still looks like a high-quality compounder temporarily treated like an overhyped story, and we think that disconnect favors the bulls.
